To further test the hypothesis that CR2 expression on naive T cells defines RTEs throughout life rather than being specific to cells generated during the neonatal period, we monitored newly generated naive CD4+ T cells in 8 multiple sclerosis (MS) patients depleted of T and B cells using alemtuzumab (24) (Figure 3A and Supplemental Figure 3A). This evidence concerns the gene CR2 and myeloid sarcoma.